BIOR vs. LPCN, UBX, FBRX, ITRM, ACST, ONCT, APRE, QLI, LUMO, and ENLV
Should you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Lipocine (LPCN), Unity Biotechnology (UBX), Forte Biosciences (FBRX), Iterum Therapeutics (ITRM), Acasti Pharma (ACST), Oncternal Therapeutics (ONCT), Aprea Therapeutics (APRE), Qilian International Holding Group (QLI), Lumos Pharma (LUMO), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.
Lipocine (NASDAQ:LPCN) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
9.1% of Lipocine shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 6.1% of Lipocine shares are held by company insiders. Comparatively, 51.0% of Biora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Lipocine had 2 more articles in the media than Biora Therapeutics. MarketBeat recorded 7 mentions for Lipocine and 5 mentions for Biora Therapeutics. Lipocine's average media sentiment score of 0.75 beat Biora Therapeutics' score of 0.66 indicating that Biora Therapeutics is being referred to more favorably in the news media.
Lipocine has higher revenue and earnings than Biora Therapeutics. Lipocine is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lipocine's return on equity of 0.00% beat Biora Therapeutics' return on equity.
Lipocine has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Lipocine received 339 more outperform votes than Biora Therapeutics when rated by MarketBeat users. Likewise, 70.29% of users gave Lipocine an outperform vote while only 66.67% of users gave Biora Therapeutics an outperform vote.
Summary
Lipocine and Biora Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Biora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biora Therapeutics Competitors List
Related Companies and Tools
